A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > BUSINESS
BUSINESS
- Desalex Most Promoted for GPs in April amid Pollen Season: Anterio
June 20, 2018
- PII Data Suggest Acucela’s Emixustat Improves Macular Edema
June 20, 2018
- Enbrel 25 mg Pen Now Available: Pfizer/Takeda
June 19, 2018
- Quizartinib Cuts Risk of Death by 24% for AML: Daiichi Sankyo
June 19, 2018
- Nichi-Iko to Roll Out Enbrel Biosimilar under License Deal with Lupin
June 19, 2018
- Onychomycosis Treatment Efinaconazole Approved in Taiwan: Kaken, Mitsubishi Tanabe
June 18, 2018
- CSL Behring Japan Chief Eyes Double-Digit Growth for Next Few Years
June 18, 2018
- Shionogi Bags Some Asian Rights for Sage’s Depression Drug
June 15, 2018
- Authorized Generics for Aimix, Cravit IV Bag Hit Shelves; Takepron Out in September
June 15, 2018
- Velcade Gx Skips Listing, Teva Takeda Says Not Ready for Launch
June 15, 2018
- Eisai Enters Agreement with 6 Institutions for Nucleic Acid Drug Discovery Research; Project Selected for CiCLE Program
June 14, 2018
- Univ. of Tokyo, Fujitsu, Kowa Discover Novel Small Molecule Compounds Using IT-Based Drug Discovery
June 14, 2018
- US FDA Accepts NDA for Sunovion’s Parkinson’s Disease Treatment
June 14, 2018
- Eisai to Launch New US Research Center for Innovative Drug Discovery in Dementia Field
June 14, 2018
- Mochida Licenses EPA Technologies to Amarin
June 13, 2018
- EA Pharma Licenses SHPT Treatment to China Firm
June 13, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Ethical Drug Sales Jump 7.6% in April on Price Revision: Crecon
June 12, 2018
- Parkinson’s Drug Azilect Now Available in Japan: Takeda
June 12, 2018
- Vortioxetine Showed Positive Results in Japan PIII with MDD Patients: Takeda/Lundbeck
June 12, 2018
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…